Patient Safety

At Zambon, patient safety is a top priority. From the earliest stages of the development of potential new drugs, and then throughout their lifecycle, our goal is to assess the efficacy and safety of Zambon products.


Before a new Zambon medicine is approved and released to the market, it is evaluated in rigorously controlled preclinical and clinical studies, which provide essential information about its safety and efficacy. In addition, once the drug is available for widespread use, Zambon monitors the safety of its products and makes every effort to ensure that any new potential safety concerns are systematically detected and then communicated to regulatory authorities so that appropriate decisions and actions are taken.


Patients should always refer to their doctor or pharmacist for medical advice about any adverse effects during treatment.

You are encouraged to report negative side effects of prescription drugs to the FDA.  Visit, or call 1-800-FDA-1088.

 You are also encouraged to report adverse events related to a Zambon product to: